MRNS Marinus Pharmaceuticals Inc.

2.54
-0.13  -5%
Previous Close 2.67
Open 2.7
52 Week Low 0.77
52 Week High 4.83
Market Cap $267,111,569
Shares 105,162,035
Float 104,861,719
Enterprise Value $231,658,633
Volume 1,368,777
Av. Daily Volume 1,275,498
Stock charts supplied by TradingView

Upcoming Catalysts

Drug Stage Catalyst Date
Ganaxolone - Marigold
CDKL5 Deficiency Disorder (CDD)
Phase 3
Phase 3
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.
Ganaxolone (Violet Study)
PCDH19-related epilepsy
Phase 3
Phase 3
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.
Ganaxolone
Tuberous Sclerosis Complex
Phase 2
Phase 2
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.

Drug Pipeline

Drug Stage Notes
Ganaxolone
Refractory status epilepticus (RSE)
Phase 2
Phase 2
Phase 3 trial to be initiated 3Q 2020.
Ganaxolone - Magnolia
Postpartum depression
Phase 2
Phase 2
Phase 2 negative data released July 23, 2019.
Ganaxolone
Focal onset seizures
Phase 3
Phase 3
Phase 3 data did not meet endpoints - June 2016
Ganaxolone
Fragile X Syndrome
Phase 2
Phase 2
Phase 2 data released June 2016. Primary endpoint not met but intends to advance development

Latest News

    • Status Epilepticus pivotal Phase 3 trial on-track to begin in Q3 2020
    • CDKL5 Deficiency Disorder Phase 3 trial results in Q3 2020
    • First patient enrolled in Phase 2 Tuberous Sclerosis Complex trial
    • Enrollment in PCDH19 proof-of-concept trial increases to 25-30 patients
    • Pipeline update webinar featuring four KOLs today at 8:00am ET

    RADNOR, Pa., June 30, 2020 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today provided a pipeline update in advance of it clinical and commercial overview webinar to be held today, Tuesday, June 30, 2020 from 8am – 10:30am Eastern Time.

    "With a final protocol in place, we are on-track…

    • Status Epilepticus pivotal Phase 3 trial on-track to begin in Q3 2020

    • CDKL5 Deficiency Disorder Phase 3 trial results in Q3 2020
    • First patient enrolled in Phase 2 Tuberous Sclerosis Complex trial
    • Enrollment in PCDH19 proof-of-concept trial increases to 25-30 patients
    • Pipeline update webinar featuring four KOLs today at 8:00am ET

    RADNOR, Pa., June 30, 2020 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today provided a pipeline update in advance of it clinical and commercial overview webinar to be held today, Tuesday, June 30, 2020 from 8am – 10:30am Eastern Time.

    "With a final protocol in place, we are on-track to begin our Phase 3 pivotal trial in status epilepticus next quarter," said Scott Braunstein, M.D., Chief Executive Officer of Marinus. "Our Phase 3 trial is designed to demonstrate both rapid onset of antiepileptic activity along with sustained status cessation, allowing physicians to focus their attention on the patients' underlying disease state and avoid the often devastating consequences of uncontrolled SE and anesthesia induced coma."

    Dr. Braunstein added, "Our oral ganaxolone program has focused on rare genetic epilepsies with a biology-driven scientific foundation underserved by current available treatment options. To that end, we have initiated a Phase 2 study in tuberous sclerosis complex-related epilepsy and are preparing for our Phase 3 data readout in CDD next quarter. We look forward to sharing further details on our clinical and commercial strategies during our pipeline update event today and are thrilled to have KOL engagement and insight as we discuss our programs." 

    Pipeline Update:

    Status Epilepticus (SE)

    • Marinus has finalized the protocol for its planned Phase 3 pivotal clinical trial in SE following its End of Phase 2 Meeting held in March 2020 and based on the successful results from its completed Phase 2 trial.
    • The Phase 3 study will be a randomized, double-blind, placebo-controlled trial in SE patients who have failed benzodiazepines and 2 or more intravenous anti-epileptic drugs (AEDs).
    • The trial will enroll 124 patients randomized to receive ganaxolone or placebo adjunctive to standard of care at approximately 80-100 U.S. sites.
    • Patients will receive a 36-hour infusion followed by a 12-hour taper for a total 48-hour treatment period, which, for patients randomized to receive ganaxolone, targets a plasma concentration of greater or equal to 500ng/mL for 12-hours (same target concentration, 50% longer duration as the Target Dose evaluated in Phase 2).
    • The co-primary endpoints for the study are (i) proportion of patients with SE cessation within 30 minutes of treatment initiation without medications for the acute treatment of SE and (ii) proportion of patients with no progression to IV anesthesia for 36 hours following treatment initiation.
    • Trial initiation on-track for Q3 2020 with topline data expected first half of 2022

    CDKL5 Deficiency Disorder (CDD)

    • Marinus remains on-track to report top‑line data from the pivotal Phase 3 Marigold Study, which is evaluating the use of oral ganaxolone in children and young adults with CDD. The global, double‑blind, placebo‑controlled, clinical trial has enrolled 101 patients between the ages of 2 and 21 with a confirmed disease‑related CDKL5 gene variant.
    • In advance of topline data, Marinus has begun preparations for an expanded access program (EAP) in CDD that will allow the Company, on positive data, to offer ganaxolone to patients  who were unable to participate in the Phase 3 study.

    Tuberous Sclerosis Complex (TSC)

    • The first patient has been enrolled in the Company's Phase 2 open‑label trial to evaluate the safety and tolerability of adjunctive ganaxolone treatment in patients with TSC. The trial is expected to enroll approximately 30 patients ages 2 to 65.
    • Patients will undergo a four‑week baseline period followed by a 12‑week treatment period where they will receive up to 600 mg of ganaxolone (oral liquid suspension) three times a day. Patients who meet eligibility criteria may continue ganaxolone treatment during a 24‑week extension to the trial.
    • The primary endpoint for the trial is percent change in 28‑day primary seizure frequency for the treatment period relative to baseline. The Company plans to analyze allopregnanolone sulfate levels as part of the trial efficacy analysis.

    PCDH19 Related Epilepsy (PCDH19-RE)

    • Marinus remains on-track to enroll 25-30 patients (an increase from its previous guidance of 15-20 patients) in the ongoing Phase 2 Violet Study evaluating allopregnanolone sulfate as a biomarker and ganaxolone as a treatment in PCDH19-RE patients.
    • The Company believes the increased patient enrollment has the potential to strengthen the ability to detect a meaningful signal as proof-of-concept for the allopregnanolone sulfate biomarker hypothesis.
    • Marinus remains on-track to report topline data from this POC trial in the first half of 2021.             

    Webinar Details:



    To listen to the live webinar at 8am ET today, please click here.

    About Marinus Pharmaceuticals



    Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders. Ganaxolone is a positive allosteric modulator of GABAA receptors that acts on a well-characterized target in the brain known to have anti-seizure, anti-depressant, and anti-anxiety effects. Ganaxolone is being developed in IV and oral dose forms intended to maximize therapeutic reach to adult and pediatric patient populations in both acute and chronic care settings. Marinus is conducting the first ever Phase 3 pivotal trial in children with CDKL5 deficiency disorder, along with a Phase 2 trial in Tuberous Sclerosis Complex, and a Phase 2 biomarker driven proof of concept trial in PCDH19-related epilepsy. The Company intends to initiate a Phase 3 trial in status epilepticus. For more information visit www.marinuspharma.com.



    Forward-Looking Statements

    To the extent that statements contained in this press release are not descriptions of historical facts regarding Marinus, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.  Words such as "may", "will", "expect", "anticipate", "estimate", "intend", "believe", and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements.  Examples of forward-looking statements contained in this press release include, among others, statements regarding our clinical development plans for ganaxolone; expected dosing in our clinical trials; the clinical development schedule and milestones; our expected timing to begin and complete enrollment in our clinical trials, including our expectation to dose the first patient in our Phase 3 clinical trial for SE in third quarter 2020; the expected trial design, target patient population and endpoints for our clinical trials; interpretation of scientific basis for ganaxolone use; timing for availability and release of data, including the expected release of data from the Marigold Study in the third quarter of 2020 and from the proof of concept study in PCDH19 in the first half of 2021; the potential safety and efficacy of ganaxolone; the therapeutic potential of ganaxolone; and our expectations regarding the effect of the COVID-19 pandemic on our business and clinical development plans; and our plans for an expanded access program for ganaxolone. Forward-looking statements in this press release involve substantial risks and uncertainties that could cause our clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements.  Such risks and uncertainties include, among others, uncertainties and delays relating to the design, enrollment, completion, and results of clinical trials; unanticipated costs and expenses; early clinical trials may not be indicative of the results in later clinical trials; clinical trial results may not support regulatory approval or further development in a specified indication or at all; actions or advice of the U.S. Food and Drug Administration may affect the design, initiation, timing, continuation and/or progress of clinical trials or result in the need for additional clinical trials; our ability to obtain and maintain regulatory approval for our product candidate; our ability to obtain and maintain patent protection for our product candidates; delays, interruptions or failures in the manufacture and supply of our product candidate; our ability to raise additional capital; the effect of the COVID-19 pandemic on our business, the medical community and the global economy; and the availability or potential availability of alternative products or treatments for conditions targeted by us that could affect the availability or commercial potential of our product candidate. Marinus undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the Company in general, see filings Marinus has made with the Securities and Exchange Commission.       

    CONTACT:   

    Sasha Damouni Ellis

    Vice President, Investor Relations & Corporate Communications

    Marinus Pharmaceuticals, Inc.

    484-253-6792

     

    Primary Logo

    View Full Article Hide Full Article
  1. RADNOR, Pa., June 24, 2020 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced it will host a webinar featuring a clinical update and commercial overview on its pipeline programs in Status Epilepticus, CDKL5 Deficiency Disorder and Tuberous Sclerosis Complex. In addition, there will be four key opinion leaders participating in the event, which will take place on Tuesday, June 30, 2020 from 8am – 10.30am Eastern Time.

    Preliminary Agenda:

    Marinus Overview  Dr. Scott Braunstein, Chief Executive Officer
        
    Status Epilepticus  Dr. Joe Hulihan, Chief Medical Officer
    Dr. Larry Hirsch, Yale Comprehensive Epilepsy

    RADNOR, Pa., June 24, 2020 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced it will host a webinar featuring a clinical update and commercial overview on its pipeline programs in Status Epilepticus, CDKL5 Deficiency Disorder and Tuberous Sclerosis Complex. In addition, there will be four key opinion leaders participating in the event, which will take place on Tuesday, June 30, 2020 from 8am – 10.30am Eastern Time.

    Preliminary Agenda:

    Marinus Overview  Dr. Scott Braunstein, Chief Executive Officer
        
    Status Epilepticus  Dr. Joe Hulihan, Chief Medical Officer

    Dr. Larry Hirsch, Yale Comprehensive Epilepsy Center

    Dr. Henrikas Vaitkevicius, Brigham and Women's Hospital

    Department of Neurology

    Dr. Alex Aimetti, Head of Scientific Affairs

        
    CDD Overview  Dr. Scott Demarest, Children's Hospital Colorado
       Dr. Joe Hulihan, Chief Medical Officer
        
    Tuberous Sclerosis  Dr. Darcy Krueger, Cincinnati Children's Hospital Medical Center
    Complex Overview  Dr. Alex Aimetti, Head of Scientific Affairs
        
    Commercial Strategy   Thomas Lyons, Vice President of Business Development & Licensing

    To register in advance and listen to the live webinar please click here.

    Lawrence Hirsch, M.D., Professor of Neurology, Chief of Division of Epilepsy and Electroencephalography (EEG), and Co-Director of the Yale Comprehensive Epilepsy Center. He has held leadership positions at the American Clinical Neurophysiology Society (ACNS), American Epilepsy Society, American Academy of Neurology and the Epilepsy Foundation, and is founder and former chair of the Critical Care EEG Monitoring Research Consortium, which now includes more than 50 centers across North America. He is lead author of the ACNS guideline on critical care EEG terminology, and has been an active researcher throughout his career, having published more than 150 original research manuscripts and more than 100 reviews, editorials or book chapters on topics including status epilepticus, EEG, and antiepileptic drugs. Dr. Hirsch is co-author of the first-ever atlas on EEG in critical care.

    Henrikas Vaitkevicius, M.D. is an Attending Neurologist in the Neurocritical Care, Hospital Neurology, Neurological Infections, Inflammatory Diseases, and Stroke Divisions of Brigham and Women's Hospital Department of Neurology. Dr. Vaitkevicius, who is also an Assistant Professor at Harvard Medical School, received his graduate and medical school training at Wayne State University in Detroit, MI. He completed his neurology residency and neurocritical care fellowship at Brigham & Women's and Mass General Hospital in Boston, MA. Dr. Vaitkevicius has appeared in 38 peer-reviewed publications, five non-peer reviewed scientific or medical materials, and in 2015 was an ad hoc reviewer for the New England Journal of Medicine. He serves as the Director of Brain Hub: Studio for Research and Innovation in Critical Care Neurology where he focuses on fostering collaborations among academic departments and pharmaceutical industries to bring novel treatments to the bedside.

    Scott Demarest, M.D. is an Assistant Professor, Pediatrics-Neurology at the University of Colorado. Dr. Demarest's research focuses on the characterization of neurogenetic conditions through phenotyping and natural history studies, development of better outcome measures as tools for both natural history studies and clinical trials and the design of disease modifying clinical trial for rare diseases. Additionally, Dr. Demarest is the PI of the International CDKL5 Clinical Research Network (ICCRN). The ICCRN includes eight US institutions and one international site in Australia all working collaboratively to develop clinical trial readiness for disease modifying trials for CDKL5 Deficiency Disorder through improved natural history data for CDKL5 and the development and validation of appropriate outcome measures for CDKL5 Deficiency Disorder.  Dr. Demarest attended medical school at the University of Texas Health Science Center in San Antonio. He completed his residency in pediatrics and child neurology at Children's National Health System in Washington, DC and his Epilepsy fellowship at Children's Hospital Colorado.

    Darcy Krueger M.D., Ph.D. is Director of the Tuberous Sclerosis Clinic, Associate Professor of Clinical Pediatrics and Neurology, and Associate Director of Research in Neurology at Cincinnati Children's Hospital Medical Center. He is a founding member of the Tuberous Sclerosis Complex Clinical Research Consortium and served as its first Director from 2011 to 2013. Dr. Krueger received PhD and MD degrees from Saint Louis University in 2000 and 2002, respectively, and completed a combined residency in pediatrics, neurology, and child neurology at Cincinnati Children's Hospital Medical Center and the University of Cincinnati College of Medicine in 2007. Dr. Krueger was a leading investigator for the landmark clinical trial using mTOR inhibitors to treat subependymal giant cell astrocytomas that led to the first ever FDA-approved treatment for TSC in 2010. Dr. Krueger leads multiple clinical research studies in TSC, including the TSC Autism Center of Excellence Network funded by the National Institutes of Health and the TS Alliance. Additional projects are aimed at better understanding the underlying mechanisms of TSC disease pathogenesis and treatment response, with the ultimate objective of developing treatment strategies that reverse or prevent disease progression and secondary complications.

    About Marinus Pharmaceuticals

    Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders. Ganaxolone is a positive allosteric modulator of GABAA receptors that acts on a well-characterized target in the brain known to have anti-seizure, anti-depressant, and anti-anxiety effects. Ganaxolone is being developed in IV and oral dose forms intended to maximize therapeutic reach to adult and pediatric patient populations in both acute and chronic care settings. Marinus is conducting the first ever Phase 3 pivotal trial in children with CDKL5 deficiency disorder, along with a Phase 2 trial in Tuberous Sclerosis Complex, and a Phase 2 biomarker driven proof of concept trial in PCDH19-related epilepsy. The Company is initiating a Phase 3 trial in status epilepticus.

               

    CONTACT: 

    Sasha Damouni Ellis

    Vice President, Investor Relations & Corporate Communications

    Marinus Pharmaceuticals, Inc.

    484-253-6792

    Primary Logo

    View Full Article Hide Full Article
  2. RADNOR, Pa., June 22, 2020 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced that management will present at SVB Leerink's CybeRx Series: 2nd Annual CNS Forum.

    Additional details can be found below:

    Title: A Pipeline Update with Scott Braunstein (CEO) and Joe Hulihan (CMO)
    Date: Tuesday, June 23, 2020
    Time: 3:20 PM Eastern Time
    Format:  Fireside chat

    About Marinus Pharmaceuticals
    Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders. Ganaxolone is a positive allosteric modulator of GABAA receptors that acts on…

    RADNOR, Pa., June 22, 2020 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced that management will present at SVB Leerink's CybeRx Series: 2nd Annual CNS Forum.

    Additional details can be found below:

    Title: A Pipeline Update with Scott Braunstein (CEO) and Joe Hulihan (CMO)
    Date: Tuesday, June 23, 2020
    Time: 3:20 PM Eastern Time
    Format:  Fireside chat

    About Marinus Pharmaceuticals

    Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders. Ganaxolone is a positive allosteric modulator of GABAA receptors that acts on a well-characterized target in the brain known to have anti-seizure, anti-depressant, and anti-anxiety effects. Ganaxolone is being developed in IV and oral dose forms intended to maximize therapeutic reach to adult and pediatric patient populations in both acute and chronic care settings. Marinus is conducting the first ever Phase 3 pivotal trial in children with CDKL5 deficiency disorder, along with a Phase 2 trial in Tuberous Sclerosis Complex, and a Phase 2 biomarker driven proof of concept trial in PCDH19-related epilepsy. The Company intends to initiate a Phase 3 trial in status epilepticus.

               

    CONTACT: 

    Sasha Damouni Ellis

    Vice President, Investor Relations & Corporate Communications

    Marinus Pharmaceuticals, Inc.

    484-253-6792

    Primary Logo

    View Full Article Hide Full Article
  3. RADNOR, Pa., June 16, 2020 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) (the "Company" or "Marinus"), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced the grant of an inducement award to a new employee. The Compensation Committee of the Board of Directors of Marinus granted Martha Manning, Esq., the Company's new Vice President, General Counsel and Secretary, a non-qualified stock option to purchase an aggregate of 300,000 shares of its common stock as an inducement material to Ms. Manning entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).

    The stock option grant has an exercise price of $2.52 per share…

    RADNOR, Pa., June 16, 2020 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) (the "Company" or "Marinus"), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced the grant of an inducement award to a new employee. The Compensation Committee of the Board of Directors of Marinus granted Martha Manning, Esq., the Company's new Vice President, General Counsel and Secretary, a non-qualified stock option to purchase an aggregate of 300,000 shares of its common stock as an inducement material to Ms. Manning entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).

    The stock option grant has an exercise price of $2.52 per share, which is equal to the closing price of Marinus' common stock on June 15, 2020, the date of grant for the stock option. The stock option will vest and become exercisable as to 25% of the underlying shares on the one-year anniversary of the date of grant, and will vest and become exercisable as to the remaining 75% of the underlying shares in 36 equal monthly installments at the end of each month following such anniversary, subject to Ms. Manning's continued employment with Marinus on such vesting dates. The stock option was granted as an inducement material to Ms. Manning entering into employment with Marinus in accordance with Nasdaq Listing Rule 5635(c)(4), and is subject to the terms and conditions of the applicable award agreement covering such grant.

    About Marinus Pharmaceuticals

    Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders. Ganaxolone is a positive allosteric modulator of GABAA receptors that acts on a well-characterized target in the brain known to have anti-seizure, anti-depressant, and anti-anxiety effects. Ganaxolone is being developed in IV and oral dose forms intended to maximize therapeutic reach to adult and pediatric patient populations in both acute and chronic care settings. Marinus is conducting the first ever Phase 3 pivotal trial in children with CDKL5 deficiency disorder, along with a Phase 2 trial in Tuberous Sclerosis Complex, and a Phase 2 biomarker driven proof of concept trial in PCDH19-related epilepsy. The Company intends to initiate a Phase 3 trial in status epilepticus. For more information visit www.marinuspharma.com.

    Forward-Looking Statements

    To the extent that statements contained in this press release are not descriptions of historical facts regarding Marinus, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as "may", "will", "expect", "anticipate", "estimate", "intend", "believe", and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Examples of forward-looking statements contained in this press release include, among others, statements regarding our clinical development plans for ganaxolone and the clinical development schedule and milestones. Forward-looking statements in this release involve substantial risks and uncertainties that could cause our clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, uncertainties and delays relating to the design, enrollment, completion, and results of clinical trials; unanticipated costs and expenses; clinical trial results may not support further development in a specified indication or at all; actions or advice of the U.S. Food and Drug Administration may affect the design, initiation, timing, continuation and/or progress of clinical trials or result in the need for additional clinical trials; our ability to obtain and maintain regulatory approval for our product candidate; delays, interruptions or failures in the manufacture and supply of our product candidate; our ability to raise additional capital; the effect of the COVID-19 pandemic on our business, the medical community and the global economy; and the availability or potential availability of alternative products or treatments for conditions targeted by us that could affect the availability or commercial potential of our product candidate. Marinus undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the Company in general, see filings Marinus has made with the Securities and Exchange Commission.          

               

    CONTACT:   

    Sasha Damouni Ellis

    Vice President, Investor Relations & Corporate Communications

    Marinus Pharmaceuticals, Inc.

    484-253-6792

    Primary Logo

    View Full Article Hide Full Article
  4. RADNOR, Pa., June 15, 2020 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat orphan seizure disorders, today announced that Martha Manning, Esq., has been appointed Vice President, General Counsel and Secretary.

    "We are thrilled to welcome Martha to our growing team at Marinus, and believe her legal experience supporting biopharma companies across all development stages will be instrumental as we navigate through our upcoming milestones for ganaxolone in orphan seizure disorders," said Scott Braunstein, M.D., Chief Executive Officer of Marinus. "Martha will bring invaluable industry leadership to our organization as we begin to plan for…

    RADNOR, Pa., June 15, 2020 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat orphan seizure disorders, today announced that Martha Manning, Esq., has been appointed Vice President, General Counsel and Secretary.

    "We are thrilled to welcome Martha to our growing team at Marinus, and believe her legal experience supporting biopharma companies across all development stages will be instrumental as we navigate through our upcoming milestones for ganaxolone in orphan seizure disorders," said Scott Braunstein, M.D., Chief Executive Officer of Marinus. "Martha will bring invaluable industry leadership to our organization as we begin to plan for and execute potential commercialization, strategic alliances and value enhancing portfolio expansion opportunities."

    Ms. Manning has spent over 20 years in the life sciences sector, providing legal advice for development stage and commercial biopharma companies. Immediately prior to joining Marinus, Ms. Manning was Executive Vice President, General Counsel and Secretary for Achillion Pharmaceuticals, Inc., where she helped to develop and execute corporate strategy, managed corporate governance for Board of Directors, and handled all legal and compliance matters. Before her tenure at Achillion, she was General Counsel for ICeutica Inc. where she was also responsible for all legal matters, including supporting corporate growth through R&D, product and clinical development and out licensing, and corporate governance. Ms. Manning has held roles that have included Chief Legal Officer for OraPharma, Inc., Vice President and General Counsel for Sandoz, Inc. (Novartis), Senior Vice President, General Counsel and Secretary for Adolor Corporation, and Business and Finance Associate for the law firm Morgan Lewis & Bockius. Ms. Manning earned her Juris Doctor degree from the University of Pennsylvania Law School and her Bachelor of Business Administration from the University of Massachusetts. She is a member of the Pennsylvania Bar.

    About Marinus Pharmaceuticals

    Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders. Ganaxolone is a positive allosteric modulator of GABAA receptors that acts on a well-characterized target in the brain known to have anti-seizure, anti-depressant, and anti-anxiety effects. Ganaxolone is being developed in IV and oral dose forms intended to maximize therapeutic reach to adult and pediatric patient populations in both acute and chronic care settings. Marinus is conducting the first ever Phase 3 pivotal trial in children with CDKL5 deficiency disorder, along with a Phase 2 trial in Tuberous Sclerosis Complex, and a Phase 2 biomarker driven proof of concept trial in PCDH19-related epilepsy. The Company intends to initiate a Phase 3 trial in status epilepticus. For more information visit www.marinuspharma.com.

    Forward-Looking Statements

    To the extent that statements contained in this press release are not descriptions of historical facts regarding Marinus, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as "may", "will", "expect", "anticipate", "estimate", "intend", "believe", and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Examples of forward-looking statements contained in this press release include, among others, statements regarding our clinical development plans for ganaxolone and the clinical development schedule and milestones. Forward-looking statements in this release involve substantial risks and uncertainties that could cause our clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, uncertainties and delays relating to the design, enrollment, completion, and results of clinical trials; unanticipated costs and expenses; clinical trial results may not support further development in a specified indication or at all; actions or advice of the U.S. Food and Drug Administration may affect the design, initiation, timing, continuation and/or progress of clinical trials or result in the need for additional clinical trials; our ability to obtain and maintain regulatory approval for our product candidate; delays, interruptions or failures in the manufacture and supply of our product candidate; our ability to raise additional capital; the effect of the COVID-19 pandemic on our business, the medical community and the global economy; and the availability or potential availability of alternative products or treatments for conditions targeted by us that could affect the availability or commercial potential of our product candidate. Marinus undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the Company in general, see filings Marinus has made with the Securities and Exchange Commission.

    CONTACT:

    Sasha Damouni Ellis

    Vice President, Investor Relations & Corporate Communications

    Marinus Pharmaceuticals, Inc.

    484-253-6792

    Primary Logo

    View Full Article Hide Full Article
View All Marinus Pharmaceuticals Inc. News